Table 1.
Basic characteristics of the included studies.
| Study | Year | Sample time (year.month) | Cases (Treat/Con) | Age (years) | Sex (male/female) | Measures (Con group) | Study design | Outcome measures | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Treat group | Treat group | Treat group | Con group | |||||||
| Huang Yuanzhi | 2019 | 2018.01–2019.01 | 40/40 | 48.5 ± 3.3 | 48.5 ± 3.3 | 21/19 | 22/18 | Isoniazid, rifampin, ethambutol, pyrazinamide | RCT | ①③④⑤⑥ |
| Liu Fang | 2018 | 2014.01–2016.01 | 23/23 | 57.7 ± 2.4 | 57.9 ± 2.4 | 12/11 | 13/10 | Isoniazid, rifampin, ethambutol, pyrazinamide | Retrospective | ①③④⑤⑥ |
| Liu Jie | 2018 | 2016.08–2017.08 | 38/38 | 20–78 | 21–78 | 21/17 | 22/16 | Isoniazid, rifampin, ethambutol, pyrazinamide | RCT | ①③④⑤⑥ |
| Li Lintao | 2016 | 2015.05–2016.04 | 43/43 | 43.4 ± 1.8 | 42.1 ± 1.6 | 23/20 | 21/22 | Isoniazid, rifampin, ethambutol, pyrazinamide, mannitol | RCT | ①②③④⑤⑥ |
| Li Yingmin | 2021 | 2018.02–2020.06 | 34/34 | 40.8 ± 4.3 | 40.1 ± 4.2 | 19/15 | 18/16 | Isoniazid, rifampin, ethambutol, pyrazinamide | RCT | ③④⑤⑥ |
| Fan Xiu Li | 2016 | 2014.07–2015.10 | 53/53 | 48.2 ± 3.3 | 48.0 ± 3.7 | 30/23 | 29/24 | Isoniazid, rifampin, ethambutol, pyrazinamide, mannitol | RCT | ①② |
| Yang Fuyun | 2018 | NP | 42/42 | 33.9 ± 4.3 | 34.8 ± 4.1 | 22/20 | 25/17 | Isoniazid, rifampin, levofloxacin | NP | ①③④⑤⑥ |
| Lin Pingli | 2015 | 2014.02–2015.01 | 48/48 | 40.1 ± 4.6 | 40.4 ± 4.1 | 20/28 | 21/27 | Isoniazid, rifampin, ethambutol, pyrazinamide, mannitol | RCT | ①②③④⑤⑥ |
| Guy E. Thwaites | 2004 | 2001.04–2003.03 | 274/271 | 15–88 | 15–84 | 168/106 | 163/108 | Isoniazid, rifampin, pyrazinamide, placebo | RCT | ①② |
| H. S. Malhotra | 2009 | 2006.01–2007.07 | 31/30 | 15–66 | 15–70 | 15/16 | 14/16 | Isoniazid, rifampin, ethambutol, pyrazinamide, placebo | Retrospective | ①② |
| Justin A. Green | 2009 | 2001.04–2003.03 | 18/19 | 19.3–40.5 | 23.0–44.0 | 8/10 | 7/12 | Isoniazid, rifampin, pyrazinamide, streptomycin, placebo | Retrospective | ①② |
Treat, treatment; Con, control; RCT, randomized controlled trial; NR, not reported; ①, effective rate; ②, adverse effects rate; ③, comparison of cerebrospinal fluid cell count after treatment; ④, comparison of protein content in cerebrospinal fluid after treatment; ⑤, comparison of glucose levels in cerebrospinal fluid after treatment; ⑥, comparison of chloride levels after treatment.